Takeda’s cytomegalovirus drug beat Roche’s Valcyte at clearing the virus in patients who had undergone an organ transplant or stem cell transplant.
Andrew Parker, Ph.D. is the new CEO of Step Pharma.
Talaris Therapeutics raised $100 million to move its cell therapy for kidney transplant patients into phase 3.
Two years after leading AnTolRx's $4 million series A, Pfizer is moving on an option to take over development of the upstart's lead candidate.
With some tweaks, a gene therapy delivered to the liver could become a new treatment for multiple sclerosis.
The outlay gives Lilly the rights to a drug designed to treat autoimmune diseases by boosting the number and activity of regulatory T cells.
Patients who undergo organ transplants may no longer have to rely on lifelong immune-suppressing drugs, if Medeor Therapeutics has its way.